We also serve customers in Indonesia, mostly by providing loan facilitation as well as in Egypt, where we provide merchant acquisition services, and in Pakistan, where we provide merchant acquisition ...

Eli Lilly owned a pre-IPO stake in TRex Bio that was the equivalent of 23.9 percent of the biotech’s outstanding stock; that stake was set to decline to 16.8 percent of TRex Bio’s outstanding shares ...

Iambic Therapeutics (IAM Proposed), a biotech targeting breast cancer and lung cancer, unveiled the terms for its $150 million IPO early today and launched the deal for pricing next week. The company ...

TRex Bio (TRXB Proposed), an Eli Lilly-backed biotech, unveiled the terms for its $125 million IPO early today: 8.33 million shares at a price range of $14.00 to $16.00 to raise $124.95 million, if ...

We are a commercial-stage medical technology company with a singular mission to transform spine surgery by advancing motion-preserving solutions for the cervical and lumbar spine. We are exclusively ...

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums), is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might ...

Accelevation Holdings (ACCV) priced its IPO at $18.00 – $2.00 below range – and sold 30 million shares – the number of shares in the prospectus – to raise $540 million on Tuesday night, Sept. 29, 2026 ...

We are a newly organized blank check company. We intend to focus our search for an acquisition target on companies involved in agentic AI, stablecoin payments and digital yield platforms. Norma Chu is ...

Oura (OURA Proposed), the maker of the Oura Ring, the world’s smallest smart ring, postponed its $2.1 billion IPO “despite strong demand, due to uncertainty in the IPO market,” the company said early ...

We develop and manufacture medical devices for tissue repair and other healing situations. Our two major products are RegenKit, a PRP preparation kit, and Cellular Matrix, a PRP-HA combination for ...

We are a newly established blank check company. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region. We will pursue opportunities ...

Our business is focused on ThyGeNEXT and ThyraMIR v2, which are genomic tests to further evaluated thyroid nodules when pathology cannot determine whether a lesion is malignant or benign. LabCorp was ...